| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Gamida Cell Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.017 |
| 52 Week High | US$2.51 |
| 52 Week Low | US$0.008 |
| Beta | 1.13 |
| 11 Month Change | -7.61% |
| 3 Month Change | -95.53% |
| 1 Year Change | -99.13% |
| 33 Year Change | -99.74% |
| 5 Year Change | -99.76% |
| Change since IPO | -99.80% |
Recent News & Updates
Recent updates
Gamida Cell shares slide after stock offering
Sep 27Gamida appoints Emergent’s former head of vaccines as new CEO
Sep 19Gamida Cell Q2 2022 Earnings Preview
Aug 12Gamida stock rises 13% as FDA grants priority review to stem cell therapy omidubicel
Aug 01Does Gamida Cell (NASDAQ:GMDA) Have A Healthy Balance Sheet?
Feb 23
Gamida Cell: Recapping A Tough Year
Nov 02Gamida Cell (NASDAQ:GMDA) Has Debt But No Earnings; Should You Worry?
Nov 02Shareholder Returns
| GMDA.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.7% | 1.6% | 2.3% |
| 1Y | -99.1% | 23.6% | 35.1% |
Return vs Industry: GMDA.Q underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: GMDA.Q underperformed the US Market which returned 25.6% over the past year.
Price Volatility
| GMDA.Q volatility | |
|---|---|
| GMDA.Q Average Weekly Movement | 38.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GMDA.Q's share price has been volatile over the past 3 months.
Volatility Over Time: GMDA.Q's weekly volatility has increased from 23% to 38% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 147 | Abbey Jenkins | www.gamida-cell.com |
Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial.
Gamida Cell Ltd. Fundamentals Summary
| GMDA.Q fundamental statistics | |
|---|---|
| Market cap | US$2.62m |
| Earnings (TTM) | -US$61.98m |
| Revenue (TTM) | US$2.67m |
1.0x
P/S Ratio0.0x
P/E RatioIs GMDA.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMDA.Q income statement (TTM) | |
|---|---|
| Revenue | US$2.67m |
| Cost of Revenue | US$9.14m |
| Gross Profit | -US$6.47m |
| Other Expenses | US$55.51m |
| Earnings | -US$61.98m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -241.92% |
| Net Profit Margin | -2,317.95% |
| Debt/Equity Ratio | -401.0% |
How did GMDA.Q perform over the long term?
See historical performance and comparison